AMGN 240816 230.00P (AMGN240816P230000) Stock Options, News & Quotes

0.01
-0.27-96.43%

15min DelayClose Aug 9 16:00 ET

0.01High0.01Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Movers and Shakers

Aug 7 07:03

Columns Today's Morning Movers and Top Ratings: SHOP, RIVN, SMCI, DIS and More

Morning Movers
Gapping up
$Shopify (SHOP.US)$ stock soared 17% after the e-commerce platform surpassed quarterly revenue expectations, with its artificial intelligence-powered tools attracting more merchants.
$Disney (DIS.US)$ stock rose by 0.16% in volatile trading as its Entertainment unit, housing Disney+, Hulu, and ESPN+, turning a profit for the first time.
Gapping down
$Super Micro Computer (SMCI.US)$ stock fell 14.2% follo...

nerdbull1669

Aug 6 02:03

Amgen (AMGN) Drug Pipeline and Horizon Integration In Focus

$Amgen (AMGN.US)$ is scheduled to announce Q2 earnings results on 06 August (Tuesday) after the market close.
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...

Weight-loss drugmakers report strong earnings: Boon or bane?

CHFANTA

Jul 30 10:47

$Amgen (AMGN.US)$ trend seems okay...hmmm wonder how well it close tmr

Meltyy

Jun 17 22:06

$Amgen (AMGN.US)$ 🚨
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO

Meltyy

Jun 7 03:39

🚨 June PDUFAs

» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...